Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial. In the VESPER-1 trial (NCT06712836), MET-097i, a glucagon-like peptide-1 ...
Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, but rates of side effects were high and many participants discontinued the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results